跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

SML2482

Sigma-Aldrich

替格瑞洛

≥98% (HPLC)

别名:

替格瑞洛, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-二氟苯基)环丙基]氨基}-5­(丙硫基)-3H-[1,2,3]-三唑并[4,5-d]吡啶基-3-yl]-5-(2-羟基乙氧基)环戊烷-1,2-二醇, (1 S ,2 S ,3 R ,5 S )-3-[7-{[(1 R ,2 S )-2-（3,4-二氟苯基）环丙基] 氨基 }-5-（丙基砜基）-3 H - [1,2,3] 三唑 [4,5- d 嘧啶-3-基]-5-（2-羟乙氧基）-1,2-环戊二醇

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H28F2N6O4S
CAS号:
274693-27-5
分子量:
522.57
MDL编号:
MFCD09954148
UNSPSC代码:
12352200
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -55 to -65°, c = 0.2 in methanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

FC1=C(F)C=C([C@]2([H])C[C@@]2([H])NC3=NC(SCCC)=NC4=C3N=NN4[C@]5([H])C[C@H](OCCO)[C@@H](O)[C@H]5O)C=C1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

InChI key

OEKWJQXRCDYSHL-FNOIDJSQSA-N

基因信息

human ... P2RY12(64805)

正在寻找类似产品? 访问 产品对比指南

一般描述

替格瑞洛(AZD6140)是一种环戊基三唑嘧啶。

生化/生理作用

替格瑞洛是一种抗血栓形成抗血小板药物，直接和可逆地竞争性抑制腺嘌呤受体P2Y12受体发挥作用。可用于治疗急性冠状动脉综合征患者。也可改善内皮功能。替格瑞洛可抑制人红细胞摄取腺苷，促进人红细胞释放腺苷三磷酸(ATP)。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000388592
0000388594
0000329672
0000329672
0000388594

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Athanasios Moulias et al.
Journal of cardiovascular pharmacology and therapeutics, 24(1), 11-17 (2018-07-12)
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门